US Pharm. 2011;36(4):42.
Hospira, Inc., announced FDA approval of docetaxel, a generic version of Sanofi-Aventis's Taxotere. Hospira's docetaxel is approved for the treatment of a variety of cancers. Sales of Taxotere totalled approximately $1.2 billion in the United States last year. The original product formulations require health care workers to take a two-step process prior to infusion. Hospira's docetaxel comes in a single-vial formulation, designed to reduce the number of handling steps in the product's preparation.
Hospira will offer 20-mg, 80-mg, and 160-mg vials of docetaxel at a 10-mg/mL concentration, the original strength that has been available for many years. Hospira already markets docetaxel in Europe and Australia.
